已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Abstract A170: Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

作者
Meghana M. Kulkarni,Jon Winter,David P. Whalley,Ian L. Dale,Christopher R. Denz,Nin Guan,Deepa Bhavsar,Andrew J. Zhang,Timothy Rasmusson,Adrian J. Fretland,Sylvie Mireille Guichard
出处
期刊:Molecular Cancer Therapeutics [American Association for Cancer Research]
卷期号:17 (1_Supplement): A170-A170
标识
DOI:10.1158/1535-7163.targ-17-a170
摘要

Abstract ATAD2 is a bromodomain (BD)-containing protein binding to chromatin at sites enriched in acetylated histones to modulate chromatin-related processes including transcription, DNA replication, and repair. ATAD2 is frequently amplified and/or overexpressed in breast cancer and is associated with aggressive disease, tumor metastasis, and poor outcome. Given the importance of the BD in targeting ATAD2 to relevant sites on the chromatin, we and others have hypothesized that the BD is essential for its mechanism of action and its targeting would have antiproliferative effects in cancer cells. The ATAD2 BD is one of the least tractable and to date reported inhibitors have been weak, nonselective, or exhibit poor cell permeability. Here we describe a potent, selective, and cell-permeable inhibitor of ATAD2 AZ4374 that modulates ATAD2 interaction with chromatin in cells and induces growth inhibition in breast cancer cell lines. AZ4374 has a potency (IC50) of 6.3 nM in the biochemical assay with >100-fold selectivity against other bromodomain-containing proteins. Chemoproteomic analysis of AZ4374 confirmed its selectivity. ATAD2 and BRD4 inhibition in cells was determined using displacement assays (NanoBRETTM) against the bromodomains. The IC50 for AZ4374 against ATAD2 was 80 nM and no inhibition of BRD4 was observed. The recently published GSK8814 was equipotent to AZ4374 in biochemical assays (IC50 ~6 nM) but less potent in the cell-based assay (IC50 ~600 nM). AZ4374 (10 µM) modulated the mRNA levels of CDK1, CDK2, and CCNE1 in EVSA-T cells (ATAD2 amplified). CRISPR/Cas9-based knockout of ATAD2 resulted in significant decrease in colony formation in breast cancer cell lines. Exposure of these cell lines to AZ4374 also reduced colony formation in a dose-dependent manner with IC50s ranging from 100 nM in SK-BR-3 to ~1µM in EVSA-T, so consistent with the potency observed in the cell-based assay. In addition, ATAD2 protacs caused a similar reduction of colony formation as AZ4374. Considering the role of chromatin modifiers in DNA damage response (DDR), we evaluated the impact of AZ4374 on the repair pathways HR and NHEJ using a CRISPR-reporter assay (traffic light reporter). A reduction in homology-directed repair was observed with 1 uM AZ4374, consistent with its biologic effect. Studies are ongoing to probe further the impact of ATAD2 inhibition on DNA repair. This is the first demonstration of highly potent and selective ATAD2 inhibition showing consistent cellular activity and biologic effect in cancer cell lines. Citation Format: Meghana M. Kulkarni, Jon Winter, David Whalley, ian Dale, Christopher Denz, Nin Guan, Deepa Bhavsar, Andrew Zhang, Timothy Rasmusson, Adrian Fretland, Sylvie M. Guichard. Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2017 Oct 26-30; Philadelphia, PA. Philadelphia (PA): AACR; Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A170.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
英姑的应助被雪白的雨竹采纳,获得10
2秒前
xiuxiuzhang发布了新的文献求助10
2秒前
3秒前
3秒前
锦七发布了新的文献求助10
4秒前
犹豫紫蓝发布了新的文献求助10
4秒前
5秒前
Ava的应助被babayega采纳,获得10
5秒前
小不胖鼠发布了新的文献求助10
5秒前
5秒前
aaa发布了新的文献求助10
6秒前
6秒前
Cakoibao的应助被科研通管家采纳,获得10
7秒前
Maestro_S的应助被Firewoods采纳,获得20
7秒前
指南针指北完成签到 ,获得积分10
7秒前
ge的应助被科研通管家采纳,获得20
7秒前
yuqingshenseu发布了新的文献求助10
8秒前
Jasper的应助被科研通管家采纳,获得10
8秒前
vera完成签到 ,获得积分10
8秒前
所所的应助被科研通管家采纳,获得10
8秒前
充电宝的应助被科研通管家采纳,获得10
8秒前
君为臣纲的应助被科研通管家采纳,获得10
8秒前
NexusExplorer的应助被科研通管家采纳,获得10
8秒前
乐乐的应助被科研通管家采纳,获得10
8秒前
fortuna发布了新的文献求助10
9秒前
CipherSage的应助被大白包子李采纳,获得10
9秒前
9秒前
和谐完成签到 ,获得积分10
9秒前
田开心完成签到,获得积分10
10秒前
10秒前
zzyyqq完成签到,获得积分10
11秒前
小不胖鼠发布了新的文献求助10
11秒前
11秒前
小橙子完成签到 ,获得积分10
11秒前
13秒前
SciGPT的应助被玩命的绝义采纳,获得10
13秒前
852的应助被安慕希好希采纳,获得30
14秒前
星睿发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158064
求助须知:如何正确求助?哪些是违规求助? 9553987
关于积分的说明 21716926
捐赠科研通 7747422
什么是DOI,文献DOI怎么找? 3426934
关于科研通互助平台的介绍 2551676
邀请新用户注册赠送积分活动 2471057